Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   36088   clinical trials with a EudraCT protocol, of which   5931   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2012-003387-43
    Sponsor's Protocol Code Number:GS-US-337-0102
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2013-02-04
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2012-003387-43
    A.3Full title of the trial
    A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infection
    Estudio de fase 3, multicéntrico, aleatorizado y abierto, para investigar la eficacia y seguridad de una combinación a dosis fija de sofosbuvir/GS-5885 ± ribavirina durante 12 y 24 semanas en pacientes con infección crónica por el VHC genotipo 1 que no han recibido tratamiento previo
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    An international study to assess the safety and efficacy of a combination of new investigational drugs in patients with chronic hepatitis C virus infection.
    Un estudio internacional para evaluar la seguridad y eficacia de una combinación de nuevos fármacos en investigación en pacientes con infección crónica por virus de la hepatitis C.
    A.4.1Sponsor's protocol code numberGS-US-337-0102
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGilead Sciences, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGilead Sciences Inc
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGilead Sciences Inc
    B.5.2Functional name of contact pointMedical Monitor
    B.5.3 Address:
    B.5.3.1Street Address333 Lakeside Drive
    B.5.3.2Town/ cityFoster City, CA
    B.5.3.3Post code94404
    B.5.3.4CountryUnited States
    B.5.4Telephone number+1650574 3000
    B.5.5Fax number+1650578 9264
    B.5.6E-mailclinical.trials@gilead.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameSofosbuvir/GS-5885 FDC
    D.3.2Product code GS-7977/GS-5885 FDC
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSofosbuvir
    D.3.9.1CAS number 1190307-88-0
    D.3.9.2Current sponsor codeGS-7977
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number400
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGS-5885
    D.3.9.2Current sponsor codeGS-5885
    D.3.9.3Other descriptive nameGS-5885
    D.3.9.4EV Substance CodeSUB32080
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number90
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Ribasphere Tablets
    D.2.1.1.2Name of the Marketing Authorisation holderThree Rivers Pharmaceuticals, LLC
    D.2.1.2Country which granted the Marketing AuthorisationUnited States
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRibasphere
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRibavirin
    D.3.9.1CAS number 36791-04-5
    D.3.9.4EV Substance CodeSUB10297MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Chronic Genotype 1 Hepatitis C Virus Infection
    Infección crónica por el virus de la hepatitis C genotipo 1
    E.1.1.1Medical condition in easily understood language
    Hepatitis C Virus Infection
    Infección por el virus de la hepatitis C
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 15.1
    E.1.2Level LLT
    E.1.2Classification code 10019751
    E.1.2Term Hepatitis C virus
    E.1.2System Organ Class 100000004848
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objectives of this study are:
    To determine the antiviral efficacy of combination treatment with sofosbuvir/GS-5885 fixed-dose combination ± RBV as measured by the proportion of subjects with SVR
    12 weeks after discontinuation of therapy (SVR12).
    To evaluate the safety and tolerability of each treatment regimen as assessed by review of the accumulated safety data
    Los objetivos principales de este estudio son:
    Determinar la eficacia antiviral del tratamiento con una combinación a dosis fija (CDF) de sofosbuvir (SOF)/GS-5885 ± RBV, medida por la proporción de pacientes con respuesta virológica sostenida 12 semanas después de la suspensión del tratamiento (RVS12).
    Evaluar la seguridad y tolerabilidad de cada régimen de tratamiento, mediante la revisión de los datos de seguridad acumulados
    E.2.2Secondary objectives of the trial
    The secondary objectives of this study are:
    To determine the proportion of subjects who attain SVR at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)
    To evaluate the kinetics of circulating HCV RNA during treatment and after treatment discontinuation
    To evaluate the emergence of viral resistance to sofosbuvir and GS-5885 during treatment and after treatment discontinuation
    To characterize the steady state pharmacokinetics of study drugs
    To assess the effect of treatment on health related quality of life
    Los objetivos secundarios de este estudio son:
    Determinar la proporción de pacientes que alcanzan una RVS a las 4 y 24 semanas de la suspensión del tratamiento (RVS4 y RVS24)
    Evaluar la cinética del ARN del VHC circulante durante el tratamiento y después de la suspensión del tratamiento
    Evaluar la aparición de resistencia viral a sofosbuvir y GS-5885 durante el tratamiento y después de la suspensión del tratamiento
    Caracterizar la farmacocinética en el estado de equilibrio para los fármacos del estudio
    Evaluar el efecto del tratamiento sobre la calidad de vida relacionada con la salud
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Pharmacokinetic Substudy:
    An intensive serial PK sample collection will be performed at the Week 2 or Week 4 on-treatment
    visit to determine the steady-state pharmacokinetics of sofosbuvir (and its metabolites GS-566500 and GS-331007), GS-5885, and RBV (if appropriate).
    Subestudio de farmacocinética:
    Se realizará una recogida intensiva seriada de muestras para FC en las visitas de la semana 2 o la semana 4 durante el tratamiento, con el fin de determinar la farmacocinética en el estado de equilibrio para sofosbuvir (y sus metabolitos GS-566500 y GS-331007), GS -5885 y RBV (si procede).
    E.3Principal inclusion criteria
    1) Willing and able to provide written informed consent
    2) Male or female, age? 18 years
    3) Body mass index (BMI) ? 18
    4) HCV RNA ? 104 IU/mL at Screening
    5) HCV treatment-naïve
    6) HCV genotype 1a, 1b, or mixed 1a/1b at Screening.
    7) Confirmation of chronic HCV infection
    8) Cirrhosis determination [up to 20% of study subjects may have cirrhosis]
    9) Liver imaging within 6 months of Baseline/Day 1 to exclude hepatocellular carcinoma (HCC) is required in patients with cirrhosis
    10) Screening ECG without clinically significant abnormalities
    12) Subject has not been treated with any investigational drug or device within 30 days of the Screening visit.
    14) All male study participants must agree to consistently and correctly use a condom while their female partner agrees to use 1 highly effective method of birth control from the date of screening until 7 months after their last dose of RBV or 90 days after their last dose of study drug if not taking RBV.
    15) Male subjects must agree to refrain from sperm donation from the date of screening until at least 7 months after the last dose of RBV or 90 days after their last dose of study drug if not taking RBV.
    16) Subject must be of generally good health, with the exception of chronic HCV infection, as determined by the Investigator.
    17) Subject must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments.
    1) Estar dispuestos y ser capaces de dar su consentimiento informado por escrito
    2) Varones o mujeres de edad mayor o igual a 18 años
    3) Índice de masa corporal (IMC) mayor o igual que 18 kg/m2
    4) ARN del VHC mayor o igual que 104 UI/ml en la selección
    5) Sin tratamiento previo para el VHC
    6) VHC genotipo 1a, 1b o mixto 1a/1b en la selección
    7) Confirmación de infección crónica por el VHC
    8) Determinación de la cirrosis [hasta el 20% de los pacientes del estudio pueden tener cirrosis]
    9) Se necesitarán pruebas de imagen hepáticas dentro de los 6 meses previos al momento basal/día 1 para descartar carcinoma hepatocelular (CHC) en los pacientes con cirrosis
    10) ECG de selección sin anomalías clínicamente significativas
    12) El paciente no ha sido tratado con ningún fármaco o dispositivo en investigación dentro de los 30 días previos a la visita de selección
    14) Todos los participantes varones del estudio deben estar de acuerdo en usar de forma constante y correcta preservativos (y su pareja femenina debe está de acuerdo en usar 1 de los métodos anticonceptivos desde la fecha de la selección hasta 7 meses después de su última dosis de RBV o 90 días después de la última dosis del fármaco del estudio si no están recibiendo RBV
    15) Los pacientes varones deben estar de acuerdo en abstenerse de la donación de esperma desde la fecha de la selección hasta al menos 7 meses después de la última dosis de RBV o 90 días después de su última dosis del fármaco del estudio si no están recibiendo RBV
    16) Los pacientes deben tener una buena salud general, a excepción de la infección crónica por el VHC, según lo determine el investigador
    17) El paciente debe ser capaz de cumplir las instrucciones posológicas para la administración del fármaco del estudio y ser capaz de completar el calendario de evaluaciones del estudio
    E.4Principal exclusion criteria
    1) Current or prior history of any of the following:
    a) Clinically-significant illness (other than HCV) or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol;
    b) Gastrointestinal disorder or post operative condition that could interfere with the absorption of the study drug;
    c) Difficulty with blood collection and/or poor venous access for the purposes of phlebotomy;
    d) Clinical hepatic decompensation (i.e., ascites, encephalopathy or variceal hemorrhage);
    e) Solid organ transplantation;
    f) Significant pulmonary disease, significant cardiac disease or porphyria;
    g) Psychiatric hospitalization, suicide attempt, and/or a period of disability as a result of their psychiatric illness within the last 5 years;
    h) Malignancy diagnosed or treated within 5 years;
    i) Significant drug allergy (such as anaphylaxis or hepatotoxicity).
    2) Pregnant or nursing female or male with pregnant female partner.
    3) Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson?s disease, alpha-1 antitrypsin deficiency, cholangitis).
    4) Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV).
    5) Donation or loss of more than 400 mL blood within 2 months prior to Baseline/Day 1
    6) Clinically-relevant drug abuse within 12 months of screening.
    7) Alcohol misuse as defined by a Alcohol Use Disorders Identification Test (AUDIT) score ? 8
    8) Contraindications to RBV therapy, including significant history of clinically significant hemoglobinopathy (e.g., sickle cell disease, thalassemia).
    9) Use of any prohibited concomitant medications within 21 days of the Baseline/Day 1 visit.
    10) Chronic use of systemically administered immunosuppressive agents (e.g., prednisone equivalent > 10 mg/day).
    11) Known hypersensitivity to RBV, GS-5885, sofosbuvir, or formulation recipients.
    1) Presencia actual o antecedentes de cualquiera de estas situaciones:
    a) Enfermedad clínicamente significativa (distinta del VHC) o cualquier otro trastorno médico importante que pueda interferir con el tratamiento, la evaluación o el cumplimiento del protocolo;
    b) Trastorno gastrointestinal o problema postoperatorio que podría interferir con la absorción del fármaco del estudio.
    c) Dificultades para la extracción de sangre y/o mal acceso venoso para los fines de flebotomía.
    d) Descompensación hepática clínica (esto es, ascitis, encefalopatía o hemorragia por varices).
    e) Trasplante de órganos sólidos;
    f) Enfermedad pulmonar significativa, enfermedad cardíaca significativa o porfiria;
    g) Hospitalización psiquiátrica, intento de suicidio y/o período de discapacidad como consecuencia de su enfermedad psiquiátrica dentro de los últimos 5 años;
    h) Neoplasia maligna diagnosticada o tratada dentro de los últimos 5 años
    i) Alergia medicamentosa significativa (como anafilaxia o hepatotoxicidad)
    2) Mujeres embarazadas o en período de lactancia o varones cuya pareja esté embarazada.
    3) Hepatopatía crónica de etiología distinta al VHC (p. ej., hemocromatosis, enfermedad de Wilson, déficit de alfa1-antitripsina, colangitis).
    4) Infección por el virus de la hepatitis B (VHC) o virus de la inmunodeficiencia humana (VIH)
    5) Donación o pérdida de más de 400 ml de sangre en el plazo de 2 meses antes del momento basal/día 1
    6) Abuso de estupefacientes clínicamente relevante dentro de los 12 meses previos a la selección
    7) Abuso de alcohol definido por una puntuación en la prueba para la identificación de los trastornos relacionados con el consumo de alcohol (Alcohol Use Disorders Identification Test - AUDIT) mayor o igual que 8
    8) Contraindicaciones al tratamiento con RBV, como antecedentes significativos de hemoglobinopatía clínicamente significativa (p. ej., enfermedad falciforme, talasemia).
    9) Uso de cualquier medicamento concomitante prohibido, dentro de los 28 días previos a la visita basal/día 1.
    10) Uso crónico de agentes inmunosupresores administrados de forma sistémica (p. ej., equivalente de prednisona > 10 mg/día)
    11) Hipersensibilidad conocida a RBV, GS-5885, sofosbuvir o los excipientes de la formulación.
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint is sustained viral response 12 weeks post last dose of any treatment (HCV RNA <LOQ 12 weeks after cessation of therapy) in the ITT population (SVR12).
    El criterio de valoración principal de eficacia es la respuesta viral sostenida 12 semanas después de la última dosis de cualquier tratamiento (ARN VHC <LIC 12 semanas después de la interrupción del tratamiento) en la población ITT (RVS12).
    E.5.1.1Timepoint(s) of evaluation of this end point
    12 weeks post last treatment dose
    12 semanas después de la última dosis del tratamiento
    E.5.2Secondary end point(s)
    1) Safety: Adverse events (AE), safety labs, electrocardiograms (ECGs) and vital signs

    2) Sustained viral response 24 weeks post last dose of any treatment (HCV RNA <LOQ 24weeks after cessation of therapy) in the ITT population (SVR24).
    1) Seguridad: Los efectos adversos (EA), las analíticas para seguridad, electrocardiogramas (ECG) y las constantes vitales

    2) La respuesta viral sostenida 24 semanas después de la última dosis de cualquier tratamiento (VHC ARN <24 semanas LIC después de su finalización) en la población ITT (RVS24).
    E.5.2.1Timepoint(s) of evaluation of this end point
    Safety and tolerability will be assessed throughout the study

    SVR24 will be assessed 24 weeks post the last treatment dose
    Seguridad y tolerabilidad se evaluarán durante el estudio

    RVS24 serán evaluados 24 semanas después de la última dosis del tratamiento
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability
    Tolerabilidad
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Comparative treatment regimens and durations
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA41
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    France
    Germany
    Italy
    Spain
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS, defined as last vist 24 weeks after discontinuation of therapy
    LVLS, definido como la última visita 24 semanas después de la interrupción del tratamiento
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months10
    E.8.9.1In the Member State concerned days15
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months10
    E.8.9.2In all countries concerned by the trial days15
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 720
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 80
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state36
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 246
    F.4.2.2In the whole clinical trial 800
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Subjects who do not achieve SVR will be eligible for enrollment in a Sequence Registry Study (GS-US-248-0123) to monitor variants in the viral population for up to 3 years.
    Subjects who achieve SVR will be eligible for enrollment in the SVR Registry Study (GS-US-248-0122) to evaluate the durability of SVR for up to 3 years post-treatment.
    Los pacientes que no alcancen una RVS serán elegibles para reclutamiento en el estudio de registro de secuencias (GS-US-248-0123) para hacer un seguimiento de la persistencia de mutaciones de resistencia durante un máximo de 3 años.
    Todos los pacientes que alcancen una RVS serán elegibles para reclutamiento en el estudio de registro de RVS (GS-US-248-0122) para evaluar la duración de la RVS durante un máximo de 3 años postratamiento.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2013-02-28
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2013-01-11
    P. End of Trial
    P.End of Trial StatusOngoing
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2019 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA